NFE2L2 and metabolic dysfunction-associated steatotic liver disease: Currently, the lower activity of Nrf2 is listed as a major mechanism underlying NAFLD, and promoting the activation of Nrf2 is suggested to be a potent therapeutic and preventative strategy to alleviate the disease [15].